Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

for six months, a timeframe for demonstrating clinical improvement that is unique in randomized controlled studies of urate-lowering therapies.  
  • Total accounts ordering KRYSTEXXA increased to 329, a gain of 189 for the quarter.

  • A comprehensive market research study of the U.S. refractory chronic gout market was completed that demonstrated a significant market for KRYSTEXXA.

  • Four abstracts were accepted for presentation at the American College of Rheumatology Congress.

  • The executive management team expanded with the addition of a very experienced Chief Medical Officer and Chief Financial Officer.

  • Financial Results of Operations for the Three Months Ended September 30, 2011Total revenues increased to $2.6 million, or 161%, for the three months ended September 30, 2011, as compared to $1.0 million for the three months ended September 30, 2010.  The higher net sales for the three months ended September 30, 2011 were the result of the Company's launch of KRYSTEXXA, which generated approximately $1.9 million in revenue for the quarter.Cost of sales increased by $4.2 million to $4.6 million for the three months ended September 30, 2011, from $0.4 million for the three months ended September 30, 2010.  The increase for the three months ended September 30, 2011 was substantially due to a $3.4 million charge against income to reserve for excess KRYSTEXXA inventory that had expiration dates such that it was unlikely the product would be sold.

    Research and development expenses decreased by $3.1 million, or 35%, to $5.9 million for the three months ended September 30, 2011, from $9.0 million for the three months ended September 30, 2010.  The decrease for the three months ended September 30, 2011 was primarily due to costs incurred in the prior year related to commercial batches of KRYSTEXXA that were expensed as research and development expense prior to the U.S. FDA approval.  
    '/>"/>

    SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
    2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
    4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
    5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
    6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
    7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
    8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
    9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
    10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
    11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
    (Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
    (Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
    Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
    (Date:8/1/2015)... ... ... The condition where veins are enlarged and gnarled is known as varicose ... Those who spend a lot of time on their feet and standing are even ... it can to create awareness and provide a cure in observance of Senior Citizen's ...
    (Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
    (Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH awards ... awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in ... products that have stood the test of time. These include lighting products, organic ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
    (Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
    Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
    ... HIV infection rates began to rise again around 2000, researchers ... this change, especially in the homosexual community. The rising numbers ... dropped due to increased awareness of the virus. A new ... cases diagnosed each year in the last decade saw a ...
    ... clinicians with expertise in polypharmacy, caregiving and more ... a free conference examining Alzheimer,s disease. The ... join with the Greater Kentucky and Southern Indiana ... Journey: Alzheimer,s Disease and Caregiving" from 9 a.m. ...
    ... , WEDNESDAY, Aug. 24 (HealthDay News) -- Using an advanced ... chemistry of the brains of people with no cognitive problems ... and other dementias. And although there is no good ... to identify those at risk is essential when treatments and ...
    ... HealthDay Reporter , WEDNESDAY, Aug. 24 (HealthDay News) ... supply or not available at all has risen dramatically, according ... these are generic drugs given by injection and used in ... cancer. These shortages are putting patients at risk and compromising ...
    ... Food and Drug Administration has cleared a new diagnostic test ... of AIDS patients stricken with cryptococcosis, a fungal meningitis. The ... of microbiology of the University of Nevada School of Medicine, ... Oklahoma. The new, rapid blood test known as the ...
    ... have increased in Pakistan,s general population, as the ... and their children, according to an international team ... The researchers raise concern that the transmission ... as indication that the virus may be spreading ...
    Cached Medicine News:Health News:Why HIV infection rates are on the rise 2Health News:UofL experts featured at free Alzheimer's disease conference Sept. 17 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 3Health News:Cancer Drug Shortages Getting Worse, FDA Says 2Health News:Cancer Drug Shortages Getting Worse, FDA Says 3Health News:FDA clears new IMMY and University of Nevada, Reno life-saving blood test 2Health News:Study of HIV increase in Pakistan could benefit other research 2
    Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
    ... HT-MegaGrowTM, an ultra-capacity bacterial growth system, ... in a high-capacity format for bacterial ... integration with Bioneer's HT-Prep™ Automatic DNA ... numerous advantages over traditional floor shakers. ...
    Inquire...
    Inquire...
    Medicine Products: